Interleukin-18 and IL-18BP in inflammatory dermatological diseases

  • Front Immunol. 2023 Jan 18:14:955369. doi: 10.3389/fimmu.2023.955369.
Xiaoyun Wang  1  2 ,  Lian Wang  1 ,  Xiang Wen  1 ,  Lu Zhang  1 ,  Xian Jiang  1  2 ,  Gu He  1  2
Affiliations
  • 1. Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China.
  • 2. Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-Related Molecular Network and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
PMID: 36742296 DOI: 10.3389/fimmu.2023.955369
Abstract

Interleukin (IL)-18, an interferon-γ inducer, belongs to the IL-1 family of pleiotropic pro-inflammatory factors, and IL-18 binding protein (IL-18BP) is a native antagonist of IL-18 in vivo, regulating its activity. Moreover, IL-18 exerts an influential function in host innate and adaptive immunity, and IL-18BP has elevated levels of interferon-γ in diverse cells, suggesting that IL-18BP is a negative feedback inhibitor of IL-18-mediated immunity. Similar to IL-1β, the IL-18 cytokine is produced as an indolent precursor that requires further processing into an active cytokine by Caspase-1 and mediating downstream signaling pathways through MyD88. IL-18 has been implicated to play a role in psoriasis, atopic dermatitis, rosacea, and bullous pemphigoid in human inflammatory skin diseases. Currently, IL-18BP is less explored in treating inflammatory skin diseases, while IL-18BP is being tested in clinical trials for Other Diseases. Thereby, IL-18BP is a prospective therapeutic target.

Keywords
IL-18; IL-18 binding protein; atopic dermatitis; bullous pemphigoid; inflammatory dermatological disease; psoriasis; rosacea.
Products